Guideline Development Discussion


Published on

Moderated by: Professor Hee Chul Park

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Guideline Development Discussion

  1. 1. Guideline Development Discussion Moderated by: Professor Hee Chul Park
  2. 2. 1. Radical therapies (40%) - resection, liver transplantation (CLT/LDLT), local ablation (RFA, PEIT) 2. Palliative therapies (40-50%) - TACE, Radiotherapy, Targeted therapy, HAIC, - Combined treatment (RT+TACE, CCRT, etc) - others (radioembolization, hormone, immunotherapy, anti-proliferative agents) 3. Symptomatic treatment (10-20%) - Best supportive care Treatment options for HCC management
  3. 3. Guidelines Mention of RT as a treatment option APASL (2009) No KLCSG (2009) Consolidate TACE, Portal invasion, Symptom palliation JSH (2005/2007/2010) 2005/palliative RT aimed at pain relief AASLD (2005/2010) 2005/one of non-curative treatment 2010/alleviate pain in bone metastasis NCCN (2012) Unresectable (unable to transplant), Inoperable local disease EASL-EORTC (2012) No evidence/under investigation Chinese Society of Liver Disease Vascular invasion/Extrahepatic spread RT in the HCC management guidelines
  4. 4. 2012 EASL-EORTC (Updated BCLC Staging) Llovet et al. J Hepatology 2012;56:908
  5. 5. 2012 NCCN NCCN Guidelines. Hepatobiliary Cancer. V2.2012. Available at:
  6. 6. KLCSG & NCC, Korea. Korean J Hepatol 2009;15(3):391-423 2009 Korean Liver Cancer Study Group
  7. 7. Chinese Society of Liver Disease
  8. 8. Suggestions by RO Experts
  9. 9. Other suggestions (RT role for HCC) Lee IJ, Seong J. Oncology 2011;81(S1):123-33 Gut and Liver 2012;6(2):139-48
  10. 10. Other suggestions (RT role for HCC) Lee IJ, Seong J. Gut and Liver 2012;6(2):139-48
  11. 11. Unsuitable for Op, TPL, RFA TACE 1-5 sessions NCT01825824 60 Gy/3 Fx NCT01850667 45~60 Gy/3 Fx NCT01850368 40 Gy/4 Fx No Clinical Trials Debulking SBRT Sum ≤ 5 cm & 3 cm from GI tract Sum ≤10 cm Ye s No Ye s No Normal Liver Dose-Constraints rV15<700 ml (CP A5), rV17<700 ml (CP A6-B7) No Incomplete TACE Complete TACE Observation
  12. 12. Dawson L. Semin Radiat Oncol 2011;21:241-246 Other suggestions (RT role for HCC)
  13. 13. Discussions
  14. 14. RT in BCLC Staging System TACE+RT/CCRT -Consolidate TACE -Salvage TACE refractoriness(SABR) -Portal invasion Palliative RT -Symptom control -Prevention of cancer related morbidity -Oligometastasis SABR/HypoFx RT/TACE+RT -Inoperable -Inaccessible -To bridge before LT -Salvage recurrence Support from evidence-making clinical trial efforts
  15. 15. 1. Clinical Indication / or situation - As ablative, curative - As palliative, for local control - As palliative, for symptom alleviation 2. RT only / As Combined Treatment - Radiotherapy Only - Combined treatment (TACE, HAIC, sorafenib, etc) 3. Technical Issues - Fractionation (SABR, HypoFx, Conventional Fx) - Conformal RT / IMRT / RT Application Guideline for HCC management
  16. 16. 17 Standardizing protocol?  What criteria do you include in selecting the patients?  What is the impact of target delineation strategies?  What dose and fractionation scheme do you typically use when performing a CK or TT treatment?  How do you choose the treatment margins for CK or TT?  In what ways do you apply image guidance and motion management into the treatment strategies?  What follow-up methods do you use in your practice?  How do you make informed treatment decisions based on the clinical evidence level?  What should be the ideal timeline of the guideline consensus?  How can we connect the guidelines to medical associations in different countries? SBRT (CyberKnife) and IG-IMRT (TomoTherapy) Consensus to questions - #XXXXXXX — Company Confidential
  17. 17. RT role for HCC
  18. 18. Ablative RT for small HCC (< 3cm) 1. SABR (Stereotaxic Ablative Body Radiotherapy - high RT dose with precision and accuracy - generally 1-4 fractions (hypofractionated RT) 2. Clinical indication - in general, within Milan criteria - unresectable/Inoperable, not transplantable - Ineligible to RF ablation due to inconspicuity, expected heat sink effect, exophytic/peripheral location with seeding risk, central location near bile duct or bowel bleeding tendency - adequate liver function reserve - sufficient distance from radiosensitive OAR - well delineated on CT or MRI for RT planning
  19. 19. Combined RT with TACE for HCC(>3 cm) 1. Two different application - salvage TACE refractoriness after repeated TACE - consolidate residual viability of HCC after TACE 2. Rationale combining RT to TACE - tumor remains viable in and around capsule1-2) - recurrence via the parasitic blood supply3) - recurrence from recanalization of embolized artery4) - presence of vascular shunting interferes effective TACE5) - chemoagents(@TACE) stays enough long to sensitize radiation effect3) 1) Hsu et al. Cancer 1986 2) Hawkins et al. Cancer 2006 3) Seong et al. Yonsei Med J 2009 4) Hoffe et al. Cancer Control 2010 5) Krishnan et al. Ann Surg Oncol
  20. 20. RT role for HCC with vascular invasion 1. Vascular invasion (common Cx of HCC) can cause - accompanying extensive vascular shunt  ineffective TACE - portal hypertension deteriorates liver function  arterial embolization can cause hepatic failure - cause lung metastasis, heart failure, and pulmonary TE 2. RT response of vascular invasion (PVTT, IVCTT) can - delay intravascular tumor growth - delay liver function deterioration by preserving vascular flow - decrease the risk of sudden death - facilitate the subsequent treatment of HCC “Sufficient RT response is mandatory for the RT effect.”
  21. 21. nodular massive with intrahepatic metastasis diffuse vascular invasion Park et al. Oncology 2011 Sub-classification of Locally advanced HCC
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.